Guggenheim Capital LLC lessened its holdings in shares of Humana (NYSE:HUM) by 16.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 230,068 shares of the insurance provider’s stock after selling 45,624 shares during the quarter. Guggenheim Capital LLC owned 0.17% of Humana worth $57,076,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also bought and sold shares of the company. Fieldpoint Private Securities LLC acquired a new stake in Humana during the 3rd quarter worth approximately $115,000. American Beacon Advisors Inc. acquired a new stake in Humana during the 4th quarter worth approximately $122,000. ClariVest Asset Management LLC acquired a new stake in Humana during the 3rd quarter worth approximately $144,000. YorkBridge Wealth Partners LLC increased its position in Humana by 99.0% during the 4th quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock worth $159,000 after purchasing an additional 297 shares in the last quarter. Finally, Daiwa SB Investments Ltd. increased its position in Humana by 44.9% during the 4th quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock worth $176,000 after purchasing an additional 220 shares in the last quarter. 96.38% of the stock is owned by hedge funds and other institutional investors.
In related news, insider M Todoroff Christopher sold 16,389 shares of the firm’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $273.37, for a total transaction of $4,480,260.93. Following the transaction, the insider now directly owns 13,447 shares in the company, valued at $3,676,006.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bruce D. Broussard sold 14,075 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $274.32, for a total value of $3,861,054.00. Following the transaction, the chief executive officer now owns 113,896 shares in the company, valued at $31,243,950.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,660 shares of company stock valued at $8,668,218. Company insiders own 0.60% of the company’s stock.
A number of analysts recently issued reports on the stock. Piper Jaffray reissued a “buy” rating and set a $313.00 target price on shares of Humana in a research report on Wednesday. ValuEngine raised shares of Humana from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Zacks Investment Research downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. JPMorgan Chase increased their target price on shares of Humana from $253.00 to $271.00 and gave the stock a “neutral” rating in a research report on Monday, February 12th. Finally, Deutsche Bank increased their price objective on shares of Humana from $259.00 to $270.00 and gave the company a “hold” rating in a research report on Friday, February 9th. Seven investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $272.21.
Humana stock opened at $283.73 on Friday. The company has a market cap of $39,514.02, a PE ratio of 24.23, a price-to-earnings-growth ratio of 1.55 and a beta of 0.97. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.85. Humana has a 52 week low of $209.91 and a 52 week high of $293.35.
Humana (NYSE:HUM) last released its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.06. The company had revenue of $13.19 billion during the quarter, compared to analysts’ expectations of $13.14 billion. Humana had a return on equity of 16.13% and a net margin of 4.55%. The business’s revenue was up 2.4% on a year-over-year basis. During the same period in the prior year, the business posted $2.34 EPS. analysts forecast that Humana will post 13.84 earnings per share for the current year.
Humana declared that its Board of Directors has initiated a stock buyback program on Thursday, December 14th that permits the company to buyback $3.00 billion in outstanding shares. This buyback authorization permits the insurance provider to purchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Friday, March 30th will be paid a dividend of $0.50 per share. This is a boost from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 annualized dividend and a dividend yield of 0.70%. The ex-dividend date is Wednesday, March 28th. Humana’s dividend payout ratio is 17.08%.
ILLEGAL ACTIVITY WARNING: “Humana (NYSE:HUM) Shares Sold by Guggenheim Capital LLC” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/guggenheim-capital-llc-has-57-08-million-holdings-in-humana-inc-hum.html.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.